Identifying and characterizing the germinal genetic landscape of men with prostate cancer: A real-life, retrospective, multicenter study.
Identifying inherited cancer-risk genes in prostate cancer patients enables PARP inhibitor access and family screening in those who need it most.
This multicenter retrospective study characterizes the germline genetic landscape of men with prostate cancer from 8 Israeli centers, identifying the prevalence of pathogenic variants in BRCA1/2, ATM, and other DNA repair genes. The real-world data provides guidance for germline testing strategies and helps identify patients eligible for PARP inhibitor therapy and hereditary cancer surveillance.
What the study was
- Study design
- Multicenter retrospective cohort
- Population
- Men with prostate cancer undergoing germline genetic testing, 8 Israeli centers
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Genetics in medicine open
Why it surfaced
BRCA/ATM germline testing in prostate cancer directly informs olaparib/rucaparib eligibility and familial risk counseling. Real-world multicenter Israeli data fills gaps for non-Ashkenazi populations. PMC full text available.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.